Underwriting AgreementUnderwriting Agreement • September 21st, 2022 • Clearmind Medicine Inc. • Pharmaceutical preparations • New York
Cooperation AgreementCooperation Agreement • September 21st, 2022 • Clearmind Medicine Inc. • Pharmaceutical preparations
This Cooperation Agreement (“Agreement”) is entered into as of March 7, 2022 (“Effective Date”) between Scisparc Ltd. with an office at 20 Raoul Wallenberg St. Building A, 2nd Fl. (“Scisparc”) and ClearMind Medicine Inc. with offices at 101 – 1220 W 6 Ave Vancouver, BC V6H 2R8, on behalf of itself and its affiliates (“CM”). Each shall be referred hereinafter as “Party” and together – as “Parties”.
FORM OF INDEMNITY AGREEMENTIndemnification Agreement • September 21st, 2022 • Clearmind Medicine Inc. • Pharmaceutical preparations • British Columbia
NOW THEREFORE, in consideration of the premises and the covenants and agreements herein contained, the parties agree as follows:
ContractPurchase Warrant Agreement • September 21st, 2022 • Clearmind Medicine Inc. • Pharmaceutical preparations • New York
THE REGISTERED HOLDER OF THIS PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE WARRANT FOR A PERIOD OF ONE HUNDRED EIGHTY DAYS FOLLOWING [●], 2022 (THE “EFFECTIVE DATE”) TO ANYONE OTHER THAN (I) AEGIS CAPITAL CORP. OR A SELECTED DEALER IN CONNECTION WITH THE OFFERING FOR WHICH THIS PURCHASE WARRANT WAS ISSUED TO THE UNDERWRITER AS CONSIDERATION (THE “OFFERING”), OR (II) A BONA FIDE OFFICER OR PARTNER OF AEGIS CAPITAL CORP.
AMENDMENT TO THE SUBSCRIPTION AGREEMENTSubscription Agreement • September 21st, 2022 • Clearmind Medicine Inc. • Pharmaceutical preparations
THIS AMENDMENT (the “Amendment”) to the Subscription Agreement dated February 3, 2022 (the “Agreement”) is made on June 29, 2022, by and between Clearmind Medicine Inc. (the “Corporation”) and Medigus Ltd. (the “Investor”, and together with the Corporation, the “Parties”).
